Current status of topical antiretroviral chemoprophylaxis

Current Opinion in HIV and AIDS

Volumn 7, Issue 6, 2012, Pages 520-525

  Van Damme, Lut ^a   Szpir, Michael ^a  

^a FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

antiretrovirals; clinical trials; HIV; microbicides; topical preexposure prophylaxis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DAPIVIRINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MARAVIROC; MIV 150; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; CHEMOPROPHYLAXIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; GEL; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RATE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; VAGINA RING;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, TOPICAL; ANILIDES; ANTI-HIV AGENTS; CHEMOPREVENTION; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; FURANS; HIV INFECTIONS; HUMANS; ORGANOPHOSPHONATES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84868459648     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283582ca7     Document Type: Review

References (45)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
2. Gengiah TN, Baxter C, Mansoor LE, et al. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs 2012; 21:695-715.
3. Mehendale S, Deshpande S, Kohli R, et al. Acceptability of coitally-associated versus daily use of 1% tenofovir vaginal gel among women in Pune, India. Int Health 2012; 4:63-69.
4. Moss JA, Baum MM, Malone AM, et al. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. AIDS 2012; 26:707- 710.
5. Schwartz JL, Rountree RW, Kashuba ADM, et al. A multicompartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011; 6:e25974.
6. Williams BG, Abdool Karim SS, Karim QA, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 2011; 58:207-210.
7. Bunge K, Macio I, Meyn L, et al. The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781. J Acquir Immune Defic Syndr 2012; 60:337-343.
8. Parikh UM, Dobard C, Sharma S, et al. Complete protection from repeated vaginal simian-human deficiency virus exposures in macaques by topical gel containing tenofovir alone or with emtricitabine. J Virol 2009; 83:10358- 10365.
9. Lewi P, Heeres J, Arien K, et al. Reverse transcriptase inhibitors as microbicides. Curr HIV Res 2012; 10:27-35.
10. Singer R, Derby N, Mawson P, et al. An EVA vaginal ring containing the NNRTI MIV-150 protects against SHIV-RT infection in vivo. In: Proceedings of the18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2 2011; Boston, Massachusetts, USA. .
11. Singer R, Derby N, Rodriguez, et al. The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol 2011; 85:5504-5512. doi: 10.1128/JVI.02422-10
12. Forbes CJ, Lowry D, Geer L, et al. Nonaqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 2011; 156:161-169.
13. Malcolm RK, Veazey RS, Geer L, et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 2012; 56:2251-2258.
14. Pirrone V, Thakkar N, Jacobson JM, et al. Combinatorial approaches to the prevention and treatment of HIV-1 Infection. Antimicrob Agents Chemother 2011; 55:1831; doi: 10.1128/AAC.00976-10.
15. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008; 8:685-697.
16. Schader SM, Colby-Germinario SP, Schachter J, et al. Synergy against drugresistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. AIDS 2011; 25:1585-1594.
17. Microbicide Trials Network. MTN 013/IPM 026 (web page). http://www. mtnstopshiv.org/studies/2241. [Accessed 30 July 2012]
18. Akil A. Development and characterization of tenofovir-maraviroc combination film for vaginal application. In: proceedings of the International Microbicides Conference; April 15-18 2012; Sydney, Australia.
19. Hendrix C, Minnis A, Guddera V, et al. MTN- A Phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. [abstract 35LB]. In: Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2 2011; Boston, Massachusetts, USA. http://www.retroconference.org/2011/Abstracts/42418.htm. [Accessed 26 December 2011]
20. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral preexposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378:279-281.
21. Ferguson LM, Rohan LC. The importance of the vaginal delivery route for antiretrovirals in HIV prevention. Ther Deliv 2011; 2:1535-1550.
22. Adams JL, Kashuba ADM. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol 2012; 26:451-462. doi: 10.1016/j.bpobgyn.2012.01.004.
23. Fuchs EJ, Lee LA, Torbenson MS, et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis 2007; 195:703-710.
24. Rohan LC, Moncla BJ, Kunjara Na, Ayudhya RP, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PloS ONE 2010; 5:e9310.
25. Dezzutti CS, Rohan LC, Wang L, et al. Reformulated tenofovir gel for use as a dual compartment microbicide. Journal Antimicrob Chemother 2012. [Epub ahead of print] doi: 10.1093/jac/dks173.
26. Cohen J, Brache V, Cochon L, et al. Comparative safety study of prefilled, plastic and user-filled, paper vaginal applicators with candidate microbicide, tenofovir 1% gel. In: Proceedings of the International Microbicides Conference; 15-18 April 2012; Sydney, Australia.
27. Yoo JW, Lee CH. Drug delivery systems for hormone therapy. J Control Release 2006; 112:1-14.
28. Gunawardana M, Moss JA, Smith TJ, et al. Microbial biofilms on the surface of intravaginal rings worn in nonhuman primates. J Med Microbiol 2011; 60:828-837.
29. Agashe H, Hu M, Rohan L. Formulation and delivery of microbicides. Curr HIV Res 2012; 10:88-96.
30. Ham AS, Rohan LC, Boczar A, et al. Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm Res 2012; 29:1897-1907.
31. Johnson TJ, Srinivasan P, Albright TH, et al. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2012; 56:1291- 1299.
32. Nel AM, Mitchnick LB, Risha P, et al. Acceptability of vaginal film, softgel capsule, and tablet as potential microbicide delivery methods among African women. J Womens Health (Larchmt) 2011; 20:1207- 1214.
33. Patton D, Cosgrove Sweeney Y, Anders N, et al. Pharmacokinetics of vaginally applied tenofovir formulations: plasma uptake. In: Proceedings of the International Microbicides Conference; 15-18 April 2012; Sydney, Australia.
34. Microbicide Trials Network. MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women (Nov 25, 2011). http://www.mtnstopshiv.org/node/3909. [Accessed 11 July 2012]
35. Microbicide Trials Network. VOICE (MTN 003). http://www.mtnstopshiv.org/ news/studies/mtn003. [Accessed 11 July 2012]
36. Swanson M, Garcia-Martinex V. Cell-associated vaginal HIV transmission is highly efficient and not prevented by topically applied 1% tenofovir [abstract 565].In: Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March, 2012; Seattle, Washington, USA. http://www. retroconference.org/2012b/Abstracts/43046.htm. [Accessed 11 July 2012]
37. AVAC. Microbicide clinical trials. http://www.avac.org/ht/d/sp/i/325/pid/ 325 [Accessed 24 June 2012]
38. International partnership for microbicides. First efficacy trial of a microbicide ring to prevent HIV is underway [press release];13 June 2012. http://www.ipmglobal.org/publications/first-efficacy-trial-microbicide-ring- preventhiv- underway. [Accessed 10 July 2012]
39. Microbicide Trials Network. ASPIRE - a study to prevent infection with a ring for extended use. http://www.mtnstopshiv.org/news/studies/mtn020/ backgrounder. [Accessed 11 July 2012]
40. FACTS Consortium. FACTS 001 study. http://www.facts-consortium.co.za/? page-id=83. [Accessed 30 July 2012]
41. Abdool Karim. CAPRISA 004 two years on: Ten key lessons & their implications. In: Proceedings of the Presentation at the Microbicides 2012 conferences; 15 April 2012; Sydney, Australia. http://www.microbicides 2012.org/images/pdfs/m2012%20-%20abdool%20karim%20-%20caprisa %20004%20lessons.pdf [Accessed 10 July 2012]
42. Carballo-Dieguez A, Giguere R, Dolezal C, et al. 'Tell juliana': acceptability of the candidate microbicide Vivagel((r)) and two placebo gels among ethnically diverse, sexually active young women participating in a Phase 1 Microbicide Study. AIDS Behav 2011. doi: 10.1007/s10461-011-0028-6
43. Matthews L, Sibeko S, Mansoor L. Pregnant women have poorer adherence to study gel in CAPRISA 004, a Phase IIB randomized controlled trial of 1% tenofovir gel. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012. http://www.retroconference.org/2012b/ Abstracts/43363.htm [Accessed 10 July 2012]
44. Fischer W, Hunt G, Sibeko S, et al. Tenofovir resistance mutation frequencies assessed by deep pyrosequencing of plasma virus from breakthrough hiv infections: CAPRISA 004 Microbicide Trial. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle. http://www.retroconference.org/2012b/Abstracts/43477. htm [Accessed 10 July 2012]
45. Wei X, Morris L, Naranbhai V, et al. Sensitive tenofovir resistance screening of HIV-1 from the genital tract of women with breakthrough infections: CAPRISA 004 tenofovir gel trial. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle. http://www.retroconference.org/2012b/Abstracts/44025.htm [Accessed 11 July 2012]